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The common cause of death in non-insulin-dependent diabetes mellitus (NIDDM) 
is ischemic heart disease. It is known that the increase in the occurrence of 
coronary heart disease in the diabetic is particularly striking among women， and 
here diabetes appears to reduce the favored status of women1，2l. In the general 
population the concentrations of plasma total cholesterol and low-density lipoprotein 
(LDL) cholesterol are positively associated with the prevalence of coronary heart 
disease3l . In practice， postmenopausal women have high levels of plasma cholesterol 
than men of the same age4l， and several investigators5~8l and we9l have observed 
higher levels of plasma cholesterol in diabetic women than those in diabetic men. 
Despite the potential importance of elevated plasma cholesterol in postmenopausal 
women， hypercholesterolemia in this population has received less attention. 
Pravastatin， an inhibitor of the rate-limiting enzyme for cholesterol biosynthesis， 3 
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase， isnow used for 
treatment of hypercholesterolemia. However， the effect of pravastatin on lipid 
metabolism in postmenopausal hypercholesterolemia associated with NIDDM patients 
remains to be fully elucidated. The present study was designed to determine 
whether or not hypercholesterolemic women respond effectively to low doses of 
pravastatin. 
Subjects and methods 
Subjects 
The postmenopausal state was defined as the absence of menses for at least 1 year 
before enrollment into the study. Sixty-one postmenopausal hypercholesterolemic 
subjects (above 240 mg/dl) associated with NIDDM were selected from a large 
number of patients in our diabetic clinic， and divided into three groups; group 1 
was 50-59 yr (n = ll)， group 2 was 60-69 yr (n =25) and group 3 was 70-79 yr 
(n =25) . The patients were hypercholesterolemic despite low fat and low cholesterol 
diet. The diabetes was stable before entry into the study. None of the postmenopausal 
subject was on estrogen replacement therapy. Eight premenopausal hypercholesterolemic 
NIDDM patients (40-49 yr) were selected as a control group. Clinical characteristics 
of diabetic su bjects were shown in Table 1. 
pravastatin (5 mg twice a day) for 12 months. 
The su bjects were administered 
They were not taking any drugs to 
lower plasma lipid concentrations. Patients with evidence of abnormal hepatic or 
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renal function and of heavy drinkers (alcohol intake was above 50 g/ day) were 
excluded. Diet and the dose of insulin or oral hypoglycemic agents were not 
changed during the study. 
Measuremenls 
The venous blood sample was taken after a 12-14 hr overnight fast， and plasma 
lipids were measured. Determinations of blood cell count， plasma creatinine， blood 
urea nitrogen， transaminases， creatine phosphokinase， alkaline phosphatase and 
lactic dehydrogenase were performed at each blood sampling. The percentage of the 
glycosylated hemoglobin (HbA1C) content was measured by affinity chromatography 
(normal range is 4-6弘). Plasma total cholesteropOl and triglyceridel were determined 
enzymatically. High density lipoprotein (HDL) cholesterol was measured in the 
supernatant after precipitation of very low density lipoprotein (VLDL) and low 
density lipoprotein (LDL) in 1 ml of plasma with 50μ1 of 2 mol/l MnC12 and 50μl 
of sodium heparin. Friedewald calculation was applied to LDL cholesterol determination. 
Statistical anαlyses 
Analysis of variance， non-parametric statistics and two-tailed Student' s non-paired t 
test were used. The data are expressed as the mean + SD. 
Results 
Clinical chαracteristics in NIDDM patiel1is 
Clinical characteristics of subjects were similar in pre-and postmenopausal NIDDM 
before treatment， as shown in Table 1. Body mass index (BMI， kg/m2) was not 
changed during the study in al groups. 
Table 1 Clinical characteristics in NIDDM patients 
premenopausal postmenopausal 
control group 1 group 2 group 3 
number 8 1 25 25 
age(yr) 4. 9:t3.1 5. 7:t2. 7 64.7:t3.0 73.5士2.7
time since 6.2:t2.3 13.5:t2.6 23.4土2.1menopause (yr) 
HbAバ%) 7.6:t1.4 8.6ごと2.5 8.6土1.4 7. 8:t2. 2 
BMI 24.5土4.4 23.8士4.4 24.7土3.4 23.8:t4.1 
neuropathy 2/8 1/11 6/25 4/25 
retinopathy 2/8 1/11 6/25 6/25 
nephropathy 1/8 1/11 4/25 4/25 
diet 4/8 6/11 12/25 11/25 
sulfonylurea 2/8 3/11 12/25 10/25 
insulin 2/8 2/11 1/25 4/25 
The values are mean :t SD. 
BMI : body mass index 
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Changes in戸'lasmαlitids
Basal levels of total cholesterol in group 2 were significantly lower than those in 
controls and group 3， as shown in Fig 1. The basal levels of high density 
lipoprotein (HDL) cholesterol in group 3 were significantly higher than those in 
controls and basal levels of LDL cholesterol in group 2 were significantly lower than 
those in control， as shown in Figs. 2 and 3. The basal levels of triglyceride were 
similar in al groups， as shown in Fig. 4. Treatment with pravastatin resulted in a 
significant decrease in plasma total cholesterol and LDL cholesterol concentrations， 
though LDL cholesterol level in control was significantly higher than that in 
postmenopausal su bjects at one month. This hypocholesterolemic effect continued 
for 12 months (Figs. 1 and 3). On therapy， total cholesterol decreased by 29.8， 
20.3， 21.8 and 21.0弘incontrols， group 1， 2 and 3， respectively， and LDL cholesterol 
decreased by 40.6， 27.7， 27.2 and 32.4弘incontrols， group 1， 2 and 3， respectively. 
Triglyceride and HDL cholesterol levels were not significantly changed in al groups 
(Figs. 2 and 4). 
Gl ycemic control 
HbA1 c concentration was not changed during the study in al groups. 
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Fig. 1. Changes in total cholesterol levels 
The bars represent means + SD. 
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o : control (40-49 yr， n = 8)， .: group 1 (50-59 yr， n =11)， 
口:group 2 (60-69 yr， nロ 25)，and薗:group 3 (70-79 yr， n =25) . 
*-* and ~-~， pく0.05，* *一**and 非勢一帯非 pく0.01.
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Fig. 2. Changes in HDL cholesterol levels 
The bars represent means + SD. 
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o : control (40-49 yr， n = 8)， .: group 1 (50-59 yr， n =11)， 
口:group 2 (60-69 yr， n =25)， and闇:group 3 (70-79 yr， n =25). 
*-*， #ー#， and ~- ~， pく0.05，非詳一非非 pく0.01.
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Fig. 3. Changes in LDL cholesterol levels 
The bars represent means土 SD.
1 2 
(Month) 
o : control (40-49 yr， n = 8)， .: group 1 (50-59 yr， n = 11) ， 
口:group 2 (60-69 yr， n =25)， and圃:group 3 (70-79 yr， n =25) . 
*-*， #ー#，and ~- ~， pく0.05，* *-* *， pく0.01.
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Fig. 4. Changes in triglyceride levels 
The bars represent means + SD. 
(Month) 
o : control (40-49 yr， n = 8)， .: group 1 (50-59 yr， n =11)， 
口:group 2 (60-69 yr， n =25)， and • : group 3 (70-79 yr， n =25). 
*-* and #ー#， pく0.05，非非一非非 pく0.01.
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Effects of a small dose of pravastatin treatment on plasma lipid levels were not 
significantly different from each other between premenopausal and postmenopausal 
hypercholesterolemic diabetic subjects， though the decreasing effects of pravastatin 
on total cholesterol and on LDL cholesterol were slightly weak in postmenopausal 
diabetic subjects compared with in premenopausal diabetic subjects. These results 
suggest that a small dose of pravastatin is useful for the treatment of postmenopausal 
hypercholesterolemia in NIDDM patients. The present study demonstrates the fact 
that time since menopause does not affect the hypocholesterolemic effect of a small 
dose of pravastatin. 
There have been no reports whether or not the mode of diabetic therapy influences 
the cholesterol-lowering effect of pravastatin. A1though the number of subjects was 
very small in the present study， pravastatin showed similar cholesterol-lowering 
effects in diet-， sulfonylurea-， and insulin-treated NIDDM subjects. It has been 
reported that therapy with inhibitors of HMG-CoA reductase caused a 20-30覧
decrease in the plasma concentration of triglyceride in familial hypercholesterolemic 
patients12~14) and in NIDDM patients15，16). Plasma triglyceride levels， however， 
were not significantly changed after treatment in the present study. This may be 
because the present NIDDM patients have relatively low plasma levels of triglyceride. 
Pravastatin treatment did not affect the glycemic control because HbA1c concentration 
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did not change during the study. N 0 adverse drug experiences were reported. 
Clinical and laboratory examinations did not reveal any side effect of pravastatin. 
Thus pravastatin is safely available for postmenopausal hypercholesterolemia 
associated with diabetes mellitus. 
Postmenopausal diabetic women have high levels of plasma cholestero14~9) ， and 
subsequently may have high risk for ischemic heart disease. Thus the potential 
importance of elevated plasma cholesterol in postmenopausal diabetic women should 
be received more attention. The author concludes that a small dose of pravastatin 
(5 mg twice a day) is useful for the treatment of hypercholesterolemia associated 
with postmenopausal NIDDM， and prevents diabetic women from higher incidence of 
ischemic heart disease. 
Summary 
To elucidate whether a small dose of pravastatin will correct postmenopausal 
hypercholesterolemia associated with NIDDM， sixty-one postmenopausal hypercholesterolemic 
women with NIDDM were treated with pravastatin (5 mg twice a day) for twelve 
months. The su bjects were divided into three groups; group 1 was 50-59 yr 
(n = 11)， group 2 was 60-69 yr (n =25) and group 3 was 70-79 yr (nロ 25).
Twelve months after treatment， plasma levels of total cholesterol decreased by 20.3， 
21. 8 and 21. 0覧ingroup 1， 2 and 3， respectively， and LDL cholesterol decreased by 
27.7， 27.2 and 32.4% in group 1， 2， and 3， respectively. Serum levels of triglyceride 
and 1-丑コLcholesterol were not significantly changed in any group during the study. 
This cholesterol-lowering effect of pravastatin was s1ightly weak， but not significantly 
different compared with that in eight premenopausal hypercholesterolemic patients 
associated with NIDDM (total cholesterol decreased by 29.8覧andLDL cholesterol 
decreased by 40.6見). HbA 1 C concentrations were not altered during the study， and 
clinical and laboratory examinations did not reveal any side effects during the study. 
The author concludes that a small dose of pravastatin appears highly effective for 
treatment of postmenopausal hypercholesterolemia associated with NIDDM patients. 
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